文献速递角膜与眼表疾病

环孢素A 0.1%治疗眼表炎症性疾病的真实世界经验

Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases.
PubMed 文献 · Br J Ophthalmol · 2021-03-09

该回顾性研究分析了2016至2019年间在英国诺丁汉Queen's Medical Centre使用Ikervis(环孢素A 0.1%)治疗眼表炎症性疾病的463例患者,平均随访14.6个月。最常见适应症为干眼病(69.5%),治疗成功率为74.1%,药物不耐受率为16.4%;干眼病疗效最高(82.0%),过敏性眼病和角膜移植术后需额外治疗的风险显著高于干眼病。

要点

  • Ikervis治疗眼表炎症性疾病总体成功率为74.1%,药物不耐受率为16.4%。
  • 干眼病疗效最高(82.0%),过敏性眼病和角膜移植术后需额外治疗风险显著增高。
  • 年龄<70岁、过敏性眼病和OMMP/SJS是不耐受的显著预测因素。

核心结论

  • Ikervis是真实世界中管理眼表炎症性疾病有用的激素节约型局部治疗。
  • 需要改善耐受性的制剂以使更多患者受益。

研究设计与样本

  • 回顾性研究,纳入2016至2019年英国诺丁汉Queen's Medical Centre接受Ikervis治疗眼表炎症性疾病且随访至少6个月的患者,共463例。

主要发现

  • 463例患者平均年龄51.1±21.6岁,女性占59.0%,平均随访14.6±9.2个月。
  • 最常见诊断为干眼病(322例,69.5%),其次为过敏性眼病(53例,11.4%)和OMMP/SJS(38例,8.2%)。
  • 治疗成功343例(74.1%),需额外治疗44例(9.5%),药物不耐受76例(16.4%)。
  • 疗效:干眼病82.0%(264例),OMMP/SJS 65.8%(25例),角膜移植术后50.0%(7例),p<0.001。
  • Logistic回归显示年龄<70岁(p=0.007)、过敏性眼病(p=0.002)、OMMP/SJS(p=0.001)为不耐受显著预测因素;过敏性眼病和角膜移植术后需额外治疗的风险分别是干眼病的8.16倍(95%CI 2.78-23.99)和13.98倍(95%CI 4.22-46.28)。

临床怎么用

  • Ikervis可作为眼表炎症性疾病(尤其是干眼病)的激素节约型局部治疗选择。
  • 对过敏性眼病、OMMP/SJS及角膜移植术后患者需关注疗效不足和不耐受风险。

局限性

  • 回顾性研究设计可能引入选择偏倚和信息偏倚。
  • 单中心研究,结果外推需谨慎。
  • 仅纳入完成至少6个月随访的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the real-world experience of using topical ciclosporin, Ikervis, in the management of ocular surface inflammatory diseases (OSIDs). METHODS: This was a retrospective study of patients treated with Ikervis for OSIDs at the Queen's Medical Centre, Nottingham, between 2016 and 2019. Relevant data, including demographics, indications, clinical parameters, outcomes and adverse events, were collected and analysed for patients who had completed at least 6 months follow-up. For analytic purpose, clinical outcome was categorised as 'successful' (resolved or stable disease), 'active disease' and 'drug intolerance'. RESULTS: 463 patients were included; mean age was 51.1±21.6 years, with a 59.0% female predominance. Mean follow-up was 14.6±9.2 months. The most common diagnosis was dry eye disease (DED; 322, 69.5%), followed by allergic eye disease (AED; 53, 11.4%) and ocular mucous membrane pemphigoid/Steven-Johnson syndrome (OMMP/SJS; 38, 8.2%). Successful treatment was achieved in 343 (74.1%) patients, with 44 (9.5%) requiring additional treatment and 76 (16.4%) reporting drug intolerance. The efficacy of Ikervis was highest in DED (264, 82.0%), followed by OMMP/SJS (25, 65.8%) and post-keratoplasty (7, 50.0%; p<0.001). Logistic regression analysis demonstrated age <70 years (p=0.007), AED (p=0.002) and OMMP/SJS (p=0.001) as significant predictive factors for Ikervis intolerance. AED and post-keratoplasty were 8.16 times (95% CI, 2.78 to 23.99) and 13.98 times (95% CI, 4.22 to 46.28), respectively, more likely to require additional treatment compared with DED. CONCLUSIONS: Ikervis is a useful steroid-sparing topical treatment for managing OSIDs in the real-world setting. Preparations with improved tolerability are needed to benefit a larger number of patients.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Deshmukh R, Ting DSJ, Elsahn A, et al. Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases. Br J Ophthalmol. 2021. PMID: 33687999. doi:10.1136/bjophthalmol-2020-317907

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。